← Back to headlines
Nuvation Bio and Eisai's Taletrectinib Application for NSCLC Accepted by EMA
The European Medicines Agency (EMA) has accepted the application from Nuvation Bio and Eisai for taletrectinib, a drug intended for the treatment of non-small cell lung cancer (NSCLC).
26 Mar, 21:26 — 26 Mar, 21:26
Sources
Showing 1 of 1 sources
